Skip to content
Clinical Trials – home
LithuaniaBack to Lithuania

Clinical trials in Alytus

9 clinical trials in Alytus, Lithuania. Every trial is listed in the EU Clinical Trials Register and updated daily.

LithuaniaOur site in LithuaniaKlinikiniai-Tyrimai.lt(opens in a new tab)
Alytus at a glance
9
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

9 trials in Alytus

Open in trial search
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Arteriosclerosis

Not recruiting
Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Other cities in Lithuania

The busiest research cities in the country

All 10 cities in Lithuania

Clinical research in Alytus

What the registry says about research in the country

01 Stroke Prevention Research

Groundbreaking research focusing on ischemic stroke prevention, particularly studying new therapeutic approaches for patients who have experienced acute non-cardioembolic strokes or high-risk transient ischemic attacks.

  • Post-stroke prevention strategies
  • Oral anticoagulation therapy
  • Mini-stroke management

Clinical investigations are evaluating novel oral medications combined with antiplatelet therapy for improved stroke prevention outcomes.

02 Cardiovascular Disease Management

Studies targeting atherosclerotic cardiovascular disease through innovative therapeutic approaches, focusing on reducing major adverse cardiovascular events in high-risk patients.

  • LDL-C level management
  • Cardiovascular death prevention
  • Heart attack risk reduction

Research aims to evaluate new treatments for preventing cardiovascular complications in patients with established vascular disease.

03 Heart Failure Research

Innovative clinical trials exploring treatments for acute decompensated heart failure, with special attention to patients with preserved and mildly reduced ejection fraction.

  • Heart failure event reduction
  • Cardiovascular mortality
  • Novel therapeutic approaches

Studies are evaluating new compounds to reduce heart failure events and improve patient outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).